Thomas Weisel Upgrades Genomic Health (GHDX) to Overweight
More News related to GHDX
- Genomic Health to Present at Piper Jaffray Health Care Conference
- Genomic Health (GHDX) Tops Q3 EPS by 7c
- Genomic Health Announces Third Quarter 2009 Financial Results and Business Progress
- Trading Radar for 11/04: Cisco (CSCO), Comcast (CMCSA), Tyco (TEL), Molson Coors (TAP) Report
- Genomic Health to Announce Third Quarter 2009 Financial Results and Host Conference Call on Wednesday, November 4, 2009
More News related to Upgrades
- ARCA Bio (ABIO) CFO Falberg Resigns
- Deere & Company (DE) Elects Sam Allen to Chairman; To Remain Pres. and CEO
- Sequenom (SQNM) Announces that Dr. Yves Ville Joins Clinical Advisory Board
- Newell Rubbermaid (NWL) Appoints Juan Figuereo to EVP and CFO
- A.C. Moore (ACMR) Hires Richard Arthur as VP of Marketing and Advertising
Thomas Weisel upgrades Genomic Health (Nasdaq: GHDX) from Marketweight to Overweight. Price target $23.
To see more analyst ratings on GHDX Click Here.
Genomic Health, Inc., a life science company, engages in the development and commercialization of genomic-based clinical diagnostic tests for cancer.
Related Categories
UpgradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
